abstract |
The compounds of formula (1) in which R ', HET-1 and HET-2 are as described in the specification and their salts and prodrugs are glycokinase (GLK) activators and are therefore useful in the treatment of, for example, diabetes 2. The processes for preparing compounds of formula (1) are also described. |